280771-83-7

Basic information

• Product Name: N-(5-chloro-2-pyridinyl)-(2-nitro)-5-fluorophenylcarboxamide
• Synonyms: N-(5-chloro-2-pyridinyl)-(2-nitro)-5-fluorophenylcarboxamide
• CAS NO: 280771-83-7
• Molecular Formula: C₁₂H₇ClFN₃O₃
• Molecular Weight: 296
• Mol File: 280771-83-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 382.633°C at 760 mmHg
• Flash Point: 185.21°C
• Appearance: /
• Density: 1.56g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.665
• CAS DataBase Reference: N-(5-chloro-2-pyridinyl)-(2-nitro)-5-fluorophenylcarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-chloro-2-pyridinyl)-(2-nitro)-5-fluorophenylcarboxamide(280771-83-7)
• EPA Substance Registry System: N-(5-chloro-2-pyridinyl)-(2-nitro)-5-fluorophenylcarboxamide(280771-83-7)

Safety Data

• Hazardous Substances Data: 280771-83-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H7ClFN3O3/c13-7-1-4-11(15-6-7)16-12(18)9-5-8(14)2-3-10(9)17(19)20/h1-6H,(H,15,16,18)

Upstream product

• 1072-98-6 5-chloro-2-pyridylamine 
• 320-98-9 5-fluoro-2-nitrobenzoic acid 

Downstream Products

• 679406-99-6 N-(5-chloro-pyridin-2-yl)-5-(4-methyl-piperazin-1-yl)-2-nitro-benzamide 
• 280773-85-5 N-(5-chloropyridin-2-yl)-5-methylthio-2-nitrobenzamide 
• 280771-84-8 2-amino-N-(5-chloropyridin-2-yl)-5-fluorobenzamide 
• 850148-17-3 N-(5-chloro-2-pyridinyl)-(2-nitro)-5-acetic acid methyl ester sulfanyl-phenylcarboxamide 

Relevant articles and documents

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor

Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three phenyl rings. A class of highly potent, selective, efficacious and orally bioavailable direct factor Xa inhibitors was discovered. These compounds were screened in hERG binding assays to examine the effects of substitution groups on the hERG channel affinity. From the leading compounds, betrixaban (compound 11, PRT054021) has been selected as the clinical candidate for development.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs

Anthranilamides 4 and 5 were designed and synthesized as selective and orally bioavailable factor Xa inhibitors. Structural modifications aimed at lowering their lipophilicity were performed at the central phenyl ring and at the S4 binding biphenyl region by incorporating water solublizing substituents. The resulting compounds (e.g., 7, 8, 14, 30a, and 32b) are highly potent in vitro, and show improved activity in human plasma-based thrombin generation assay.